Alto Neuroscience (NYSE:ANRO) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Alto Neuroscience (NYSE:ANRO) from a hold rating to a strong sell rating in a research note published on Sunday.

Several other equities analysts have also issued reports on ANRO. BTIG Research lifted their price target on shares of Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Bank of America assumed coverage on shares of Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price target on the stock. JonesTrading cut their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Wedbush lifted their price target on shares of Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Thursday. Finally, Weiss Ratings raised shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $35.50.

Alto Neuroscience Stock Performance

Shares of ANRO stock opened at $23.00 on Friday. The firm has a market cap of $806.96 million, a price-to-earnings ratio of -9.50 and a beta of 1.62. The company’s 50 day moving average is $23.23 and its 200 day moving average is $18.54. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. Alto Neuroscience has a 52-week low of $2.15 and a 52-week high of $28.44.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.24). On average, sell-side analysts anticipate that Alto Neuroscience will post -2.78 EPS for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

A number of large investors have recently made changes to their positions in ANRO. AQR Capital Management LLC purchased a new stake in shares of Alto Neuroscience during the first quarter valued at $52,000. Torren Management LLC purchased a new stake in shares of Alto Neuroscience during the fourth quarter valued at $62,000. Invesco Ltd. purchased a new stake in shares of Alto Neuroscience during the first quarter valued at $67,000. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Alto Neuroscience by 13.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after buying an additional 2,055 shares during the last quarter. Finally, Bridgeway Capital Management LLC grew its holdings in shares of Alto Neuroscience by 85.9% during the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after buying an additional 25,000 shares during the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.